Eli Lilly released its once-daily oral weight-loss pill, Foundayo (orforglipron), in the United States. The medication targets adults with obesity or those who are overweight with related health conditions. Distribution occurs through LillyDirect, telehealth providers, and partners including LifeMD and Amazon Pharmacy.
This launch intensifies competition with Novo Nordisk in the oral weight-loss market. Lilly set a starting self-pay price of $149 per month. Commercially insured patients may pay as little as $25 monthly.
Analysts updated their outlooks on April 10, 2026. Morgan Stanley raised its price target to $1,327 with an overweight rating. Rothschild & Co Redburn increased its price target to $880 with a neutral rating.